Zelluna ASA Reports Third Quarter 2026 Financial Results
Zelluna ASA released its financial results for the third quarter of 2026, highlighting progress in its ZIMA-101 clinical program.
Stocks · News reference
Zelluna ASA Awarded NOK 15.6 Million Grant by Research Council of Norway
Zelluna ASA received a NOK 15.6 million grant from the Research Council of Norway to advance the manufacturing of its TCR-NK cell therapy platform.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading